Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C. Santoro MM, et al. Among authors: perno cf. HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. HIV Med. 2013. PMID: 23668660 Free article.
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
Armenia D, Di Carlo D, Maffongelli G, Borghi V, Alteri C, Forbici F, Bertoli A, Gori C, Giuliani M, Nicastri E, Zaccarelli M, Pinnetti C, Cicalini S, D'Offizi G, Ceccherini-Silberstein F, Mussini C, Antinori A, Andreoni M, Perno CF, Santoro MM. Armenia D, et al. Among authors: perno cf. HIV Med. 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388. Epub 2016 Jun 28. HIV Med. 2017. PMID: 27353061 Free article.
Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study.
Fokam J, Mpouel Bala ML, Santoro MM, Takou D, Tala V, Beloumou G, Ngoufack ES, Chenwi C, Pabo Willy Leroi T, Njume D, Teto G, Dambaya B, Djupsa S, Sosso S, Ateba F, Kamta C, Bala L, Njom Nlend AE, Koki Ndombo P, Colizzi V, Perno CF, Ndjolo A. Fokam J, et al. Among authors: perno cf. HIV Med. 2022 Jul;23(6):629-638. doi: 10.1111/hiv.13220. Epub 2021 Dec 23. HIV Med. 2022. PMID: 34951111 Free article.
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.
Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group. Winston A, et al. HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26. HIV Med. 2016. PMID: 26611175 Free article.
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Zaccarelli M, et al. Among authors: perno cf. AIDS. 2005 Jul 1;19(10):1081-9. doi: 10.1097/01.aids.0000174455.01369.ad. AIDS. 2005. PMID: 15958840
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group. De Luca A, et al. Among authors: perno cf. Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799. Antivir Ther. 2011. PMID: 21685536
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Armenia D, et al. Among authors: perno cf. Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309. Antivir Ther. 2019. PMID: 30977466 Free article.
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, Borghi V, Gennari W, Cicalini S, Buonomini A, Teti E, Lanini S, Latini A, Sarmati L, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Armenia D, et al. Among authors: perno cf. J Glob Antimicrob Resist. 2022 Sep;30:326-334. doi: 10.1016/j.jgar.2022.06.027. Epub 2022 Jul 3. J Glob Antimicrob Resist. 2022. PMID: 35793776 Free article.
737 results